Orbimed Advisors LLC Seagen Inc. Transaction History

Orbimed Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $8.16 Million - $9.21 Million	42,600 New	42,600 $9.04 Million
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $17.7 Million - $21 Million	151,212 Added 19.83%	913,812 $117 Million
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $10.2 Million - $13.5 Million	75,100 Added 10.92%	762,600 $104 Million
Q2 2022 Aug 15, 2022	BUY	$108.81 - $179.33 $2.15 Million - $3.55 Million	19,800 Added 2.97%	687,500 $122 Million
Q1 2022 May 16, 2022	BUY	$119.61 - $157.85 $1.45 Million - $1.91 Million	12,100 Added 1.85%	667,700 $96.2 Million

Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $55.3 Million - $74 Million	387,600 Added 144.63%	655,600 $101 Million
Q3 2021 Nov 15, 2021	BUY	$142.45 - $169.82 $38.2 Million - $45.5 Million	268,000 New	268,000 $45.5 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.